Results 141 to 150 of about 5,265,812 (178)
Some of the next articles are maybe not open access.
Interactions of Growth Hormone Secretagogues and Growth Hormone-Releasing Hormone/Somatostatin
Endocrine, 2001The class of novel synthetic compounds termed growth hormone secretagogues (GHSs) act in the hypothalamus through, as yet, unknown pathways. We performed physiologic and histochemical studies to further understand how the GHS system interacts with the well-established somatostatin (SRIF)/growth hormone-releasing hormone (GHRH) neuroendocrine system for
G S, Tannenbaum, C Y, Bowers
openaire +2 more sources
Hypothalamic targets for growth hormone secretagogues
Acta Paediatrica, 1997Various novel growth hormone (GH) secretagogues have been developed. GH secretagogues release GH directly from the pituitary via a pathway distinct from that involving GH‐releasing hormone (GHRH). However, they also act centrally to activate hypothalamic neurones, and require an intact GHRH system for potent in vivo activity. Both normal and transgenic
openaire +2 more sources
GROWTH HORMONE SECRETAGOGUES: FOCUS ON THE GROWTH HORMONE-RELEASING PEPTIDES
Pharmacological Research, 1997This review systematically analyses recent knowledge of the biology of the growth hormone-releasing peptides. Many years before native GHRH had been isolated and sequenced, the synthesis of an enkephalin analog, devoid of any opioid activity but capable of specifically releasing GH from in vitro pituitaries, prompted the design of a number of ...
V, Locatelli, A, Torsello
openaire +2 more sources
Growth Hormone Secretagogues in Critical Illness
Hormone Research in Paediatrics, 1999Alterations within the somatotropic axis occurring during the course of critical illness follow a biphasic pattern. The initial stress response consists of activated growth hormone (GH) release whereas circulating levels of GH-dependent insulin-like growth factor (IGF)-I and IGF binding protein (IGFBP)-3 fall and IGFBP-1 concentrations rise.
openaire +2 more sources
New Active Series of Growth Hormone Secretagogues
Journal of Medicinal Chemistry, 2003New growth hormone secretagogue (GHS) analogues were synthesized and evaluated for growth hormone releasing activity. This series derived from EP-51389 is based on a gem-diamino structure. Compounds that exhibited higher in vivo GH-releasing potency than hexarelin in rat (subcutaneous administration) were then tested per os in beagle dogs and for their
GUERLAVAIS V. +13 more
openaire +3 more sources
Growth hormone secretagogues astherapeutic agents
Growth Hormone & IGF Research, 1999Growth hormone (GH) treatment increases growth velocity in children with GH deficiency (GHD), ~ and reverses most of the abnormalities observed in adults with GHD. 2 GH treatment has also been found to reduce body fat in obese men, 3 increase muscle mass in men over 60 years of age, 4 and partially reverse the catabolic effects of dietary energy ...
openaire +2 more sources
IDrugs : the investigational drugs journal, 2005
Growth hormone secretagogues (GHSs) are a class of synthetic compounds that increase growth hormone secretion and serum IGF-1 concentrations. The short-acting GHSs produce transient elevations in GH which lead to little or no changes in IGF-1; the long-acting GHSs stimulate pulsatile GH release due to sustained elevations of IGF-1.
openaire +1 more source
Growth hormone secretagogues (GHSs) are a class of synthetic compounds that increase growth hormone secretion and serum IGF-1 concentrations. The short-acting GHSs produce transient elevations in GH which lead to little or no changes in IGF-1; the long-acting GHSs stimulate pulsatile GH release due to sustained elevations of IGF-1.
openaire +1 more source
Growth hormone secretagogue receptor antagonists.
Expert opinion on therapeutic patents, 2012The patent claims peptidic/nonpeptidic inhibitors of the ghrelin receptor, the growth hormone secretagogue receptor (GHSR) 1A. Among these compounds, it was disclosed that the addition in some compounds of a GlyMetAla tripeptide at the N-terminus of the ghrelin peptide agonists converts them into ghrelin receptor antagonists.
openaire +2 more sources
Orally active growth hormone secretagogues: state of the art and clinical perspectives
Annals of Medicine, 1998Emanuela Arvat +2 more
exaly